A comparison of the effects of thiazolidinediones and metformin on metabolic control in patients with type 2 diabetes mellitus (Q35840613)

10 August 2017

1 reference

title

A comparison of the effects of thiazolidinediones and metformin on metabolic control in patients with type 2 diabetes mellitus (English)

1 reference

10 August 2017

1 reference

1 reference

Jochen Seufert

1

1 reference

10 August 2017

Georg Lübben

series ordinal

2

1 reference

10 August 2017

Karin Dietrich

series ordinal

3

1 reference

10 August 2017

Peter C Bates

series ordinal

4

1 reference

10 August 2017

1 June 2004

1 reference

10 August 2017

Clinical Therapeutics

1 reference

10 August 2017

26

1 reference

10 August 2017

805-818

1 reference

10 August 2017

6

1 reference

Cellular mechanisms of insulin resistance

10 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Rapid increase in the use of oral antidiabetic drugs in the United States, 1990-2001.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Differential inhibitory effects of antidiabetic drugs on arterial smooth muscle cell proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Effect of thiazolidinediones and metformin on LDL oxidation and aortic endothelium relaxation in diabetic GK rats

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Effects of combined pioglitazone and metformin on diabetes and obesity in Wistar fatty rats

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Nocturnal and postprandial free fatty acid kinetics in normal and type 2 diabetic subjects: effects of insulin sensitization therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Mechanism by which metformin reduces glucose production in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Metabolic effects of metformin in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Effects of troglitazone and metformin on glucose and lipid metabolism: alterations of two distinct molecular pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Metformin Increases AMP-Activated Protein Kinase Activity in Skeletal Muscle of Subjects With Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Role of AMP-activated protein kinase in mechanism of metformin action

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

AMP-activated protein kinase: possible target for treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

PPAR-gamma: adipogenic regulator and thiazolidinedione receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Phosphatidylinositol 3-kinase activation is required for insulin stimulation of pp70 S6 kinase, DNA synthesis, and glucose transporter translocation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Adipose tissue hormones

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Regulation of skeletal muscle morphology in type 2 diabetic subjects by troglitazone and metformin: relationship to glucose disposal

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Pioglitazone and metformin reverse insulin resistance induced by tumor necrosis factor-alpha in liver cells

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Cloning of adiponectin receptors that mediate antidiabetic metabolic effects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Effects of pioglitazone on metabolic control and blood pressure: a randomised study in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Metformin: new understandings, new uses

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Rosiglitazone reduces urinary albumin excretion in type II diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Metformin, but not thiazolidinediones, inhibits plasminogen activator inhibitor-1 production in human adipose tissue in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Advanced glycation endproducts and diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990125-7

7 January 2021

10.1016/S0149-2918(04)90125-7

Identifiers

DOI

1 reference

10 August 2017

1 reference